KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $1.3 million.

  • Nektar Therapeutics' Change in Account Payables fell 4284.44% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 4497.33%. This contributed to the annual value of $2.7 million for FY2024, which is 19251.04% up from last year.
  • Nektar Therapeutics' Change in Account Payables amounted to $1.3 million in Q3 2025, which was down 4284.44% from -$3.5 million recorded in Q2 2025.
  • Nektar Therapeutics' Change in Account Payables' 5-year high stood at $7.3 million during Q4 2022, with a 5-year trough of -$12.9 million in Q4 2021.
  • For the 5-year period, Nektar Therapeutics' Change in Account Payables averaged around -$243947.4, with its median value being $669000.0 (2023).
  • As far as peak fluctuations go, Nektar Therapeutics' Change in Account Payables tumbled by 55272.73% in 2023, and later skyrocketed by 74878.54% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Change in Account Payables (Quarter) stood at -$12.9 million in 2021, then skyrocketed by 156.33% to $7.3 million in 2022, then fell by 11.57% to $6.4 million in 2023, then crashed by 42.72% to $3.7 million in 2024, then plummeted by 65.27% to $1.3 million in 2025.
  • Its Change in Account Payables stands at $1.3 million for Q3 2025, versus -$3.5 million for Q2 2025 and $6.4 million for Q1 2025.